General Clinical Chemistry Analyzers and Accessories
Heska Corporation COMPREHENSIVE PANEL-EWRAP 6/BX
This item has a minimum qty of 2 per supplier requirements.
Nova Biomedical Corporation Thermal Paper, pHOx Ultra and Prime only
Thermal Paper, pHOx Ultra and Prime only
SHIMADZU SCIENTIFIC INS (3P ONLY) VFU2-44 FILTER F/ 4200 ANALYZR
NC3727073 VFU2-44 FILTER F/ 4200 ANALYZR
Abcam Elvitegravir, quinolone HIV integrase inhibitor, 100MG
MW 447.9 Da, Purity >99%. Elvitegravir is an inhibitor of HIV integrase. It inhibits HIV integrase from HIV 1 IIIB (IC₅₀ = 0.7 nM), HIV 2 EHO (IC₅₀ = 2.8 nM) and HIV-2 ROD (IC₅₀ = 1.1 nM) in cell free assays. Elvitegravir blocks integration of HIV cDNA via inhibition of DNA strand transfer. Active against a range of HIV sub-types and against mulit-drug resistant clinical isolates. Potent (IC₅₀ range = 0.21 - 1.15 nM) HIV antiviral activity in various cell-based assays.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GSK-690693 hydrochloride, ATP-competitive pan-Akt kinase inhibitor, 25MG
MW 425.5 Da, Purity >99%. Novel ATP-competitive pan-Akt kinase inhibitor (IC₅₀ values are 2, 13 and 9 nM for Akt1, 2 and 3 respectively). Also exhibits some inhibition of AMPK, PKA and PAK and PKC isoforms (IC₅₀ < 100 nM). Displays antiproliferative and apoptotic effects in tumor cell lines.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SRT-3025 hydrochloride, 25MG
MW 606.2 Da, Purity >=98%. SRT-3025 is a potent and selective Sirt1 activator. It inhibits RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival. SRT-3025 inhibits RANKL-induced osteoclastogenesis in bone marrow-derived macrophages (BMMs) by activating AMPK and deacetylating RelA/p65 lysine 310, critical for activation of the NF-κB signaling pathway.
The product is subject to the following: Abcam Restricted Use Statement
Abcam MM-102 (HMTase Inhibitor I x ), 25MG
MW 669.8 Da, Purity >=98%. MM-102 (HMTase Inhibitor IX) is a potent WDR5/MLL interaction inhibitor (IC50 = 2.4 nM). It has been shown to block MLL1 methyltransferase activity, reducing the expression of HoxA9 and Meis-1 genes, which are both critical MLL1 target genes in MLL1 fusion protein-mediated leukemogenesis. WD-repeat protein 5 (WDR5) is a scaffold protein commonly involved in the formation of nucleosome-modifying protein complexes with histones.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Umifenovir, 25MG
MW 477.4 Da, Purity >=95%. An indole derivative with broad-spectrum antiviral activity. It inhibits virus-mediated fusion with target membrane and blocks virus entry into target cells. It shows antiviral activity against many enveloped or non-enveloped RNA or DNA viruses with IC₅₀ values ranging from 0.41 to 16 uM. It (50 or 100 mg/kg/day) reduces mean pulmonary virus yields and the rate of mortality in mice infected with FLU-A (A/PR/8/34 H1N1). Molecular dynamics and structural analysis show that Umifenovir may target SARS-CoV-2 spike glycoprotein and may block its trimerization which will reduce cell adherence and virus entry.
The product is subject to the following: Abcam Restricted Use Statement
Heska Corporation LITHIUM HEPARIN 0.5ML 500COUNT
This item has a minimum qty of 2 per supplier requirements.
Abcam IO x 2, HIF-1alpha prolyl hydro x ylase-2 (PHD2) inhibitor, 25MG
MW 352.3 Da, Purity >98%. Potent, cell-permeable, selective HIF-1α prolyl hydroxylase-2 (PHD2) inhibitor (IC₅₀ = 21 nM). Displays over 100-fold selectivity for PHD2 over factor inhibiting HIF-1 (FIH-1) and histone demethylases JMJD2A, JMJD2C, JMJD2E and JMJD3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SGI1776, 10MG
MW 405.4 Da, Purity >99%. Novel ATP competitive inhibitor of Pim1 with IC50 of 7 nM, 50- and 10-fold selective versus Pim2 and Pim3. Preliminary results from studies treating prostate cancer cells.
The product is subject to the following: Abcam Restricted Use Statement